Lupin inks pact to acquire two inhalation brands from Sunovion for USD 75 mn

The acquisition of these two brands will expand the company's inhalation product portfolio in the US and strengthen its presence in the respiratory therapy area while continuing to provide patients access to these important medicines, Lupin said in a statement. Brovana is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/atrFcUA
via IFTTT